LAUNCH
Regimen
- Experimental
- lenvatinib + TACE
- Control
- lenvatinib alone
Population
Advanced hepatocellular carcinoma (BCLC B/C), mostly with portal vein/macrovascular invasion or extrahepatic spread
Key finding
mOS 17.8 vs 11.5 mo (HR 0.45, P<0.001); mPFS 10.6 vs 6.4 mo; ORR 54% vs 25%. Proof-of-concept for TKI + TACE before the full IO+TKI+TACE era; largely BCLC-C population (most had MVI).
Source: PMID 35921605